What question did this study set out to answer?

To assess the efficacy and safety of Bulumtatug Fuvedotin in combination with Toripalimab in treating recurrent or metastatic cervical cancer.

July 4, 2026Open Access

36P Preliminary results of bulumtatug fuvedotin (BFv, 9MW2821) in combined with toripalimab in patients with recurrent or metastatic cervical cancer: A cohort from a phase Ib/II clinical study

Key Points

To assess the efficacy and safety of Bulumtatug Fuvedotin in combination with Toripalimab in treating recurrent or metastatic cervical cancer.
Open-label design
Multicenter setting
Single-arm clinical study
BFv demonstrated promising antitumor activity in cervical cancer.
The combination treatment was well tolerated by patients.
Preliminary safety results indicate manageable side effects.

Abstract

Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation nectin-4 antibody-drug conjugate (ADC) has demonstrated promising antitumor activity and is well tolerated in patients with cervical cancer (CC). Here, we present preliminary efficacy and safety results from an open-label, multicenter, single-arm clinical study combining BFv with Toripalimab in patients with recurrent or metastatic CC.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper